The first patient has been treated in a phase 2 trial investigating IBE-814 IVT in patients with diabetic macular edema or macular edema due to retinal vein occlusion, according to a press release from Ripple Therapeutics.
IBE-814 IVT is designed to release a sustained low dose of dexamethasone from an intravitreal implant to the retina for about 6 months.
The multicenter, single-masked, dose-ranging RIPPLE-1 study will evaluate the safety and efficacy of the implant in two dosage regimens. Up to 50 eyes of 50 patients with DME or RVO in Australia and New Zealand will be enrolled and evaluated